Review Date Extension: The FDA has extended Aldeyra's New Drug Application (NDA) target action date for dry eye treatment to March 16, 2026, reflecting complexities in the regulatory review process that may impact the company's future market launch timing.
Clinical Trial Results: Although the clinical trial for dry eye disease supported the activity of reproxalap, it failed to meet the primary endpoint, indicating uncertainty for the product in market competition, which could affect investor confidence.
Safety Data Submission: The safety data submitted by Aldeyra on August 21, 2025, was considered a major amendment to the NDA, demonstrating the company's efforts to meet FDA requirements, but it may also prolong the approval timeline, impacting cash flow.
Label Draft Feedback: The FDA has provided Aldeyra with a draft of the prospective label, and if no major deficiencies are identified, proposed labeling requests are expected by February 16, 2026, indicating that the FDA's review of the drug is still ongoing, which may influence market expectations.
ALDX
$3.99+Infinity%1D
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALDX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ALDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALDX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.540
Low
7.00
Averages
8.67
High
10.00
Current: 4.540
Low
7.00
Averages
8.67
High
10.00
BTIG
Thomas Shrader
Strong Buy
Maintains
$11 → $9
2025-04-07
Reason
BTIG
Thomas Shrader
Price Target
$11 → $9
2025-04-07
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$10
2025-04-04
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$10
2025-04-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$10
2025-03-03
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$10
2025-03-03
Reiterates
Strong Buy
Reason
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
